Spooner C H, Pickard A S, Menon D
Division of Emergency Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.
Med Care. 2000 Sep;38(9):948-58. doi: 10.1097/00005650-200009000-00008.
The objective of this study was to develop an instrument that will assist in evaluating the methodological quality of drug utilization reviews (DURs) and studies of prescribing appropriateness.
An expert committee followed accepted steps for developing and testing new instruments. Consultations on content, face validity, and scoring of items were solicited from external experts. Seven raters tested an initial version; subsequently, a refined instrument was designed. The Edmonton Quality Assessment Tool for Drug Utilization Reviews (EQUATDUR-2) evaluates 3 domains: sample selection (1 item), data collection (1 item), and data analysis (3 items). Sixteen raters tested EQUATDUR-2 on a random sample of DURs.
The study measures were reliability-using random effects interclass correlation coefficients for ratings by individual raters (ICC2,1) and the mean of ratings (ICC2,k)-and variability between DUR quality levels and rater groups.
There were significant differences in methodological quality (P <0.001) and in mean scores comparing low-, moderate-, and high-quality DURs. Nonmethodologists' ratings exhibited significant variability (P = 0.03) and tended to be higher. Agreement varied for individual items (ICC2,1, 0.22 to 0.44; ICC2,k, 0.81 to 0.91) and for mean summary ratings (ICC2,1, 0.42 [95% CI, 0.28 to 0.61]; ICC2,k, 0.92 [95% CI, 0.86 to 0.96]). The average time to rate each DUR was 10.0 minutes (95% CI, 9.2 to 10.9).
EQUATDUR-2 is a succinct, self-administered instrument with evidence of validity and reliability. We recommend that > or =2 raters independently assess each DUR and resolve disagreements by consensus. EQUATDUR-2 will help clinicians and decision makers to evaluate the quality of DUR studies and provide a framework for enhancing rigor in the design, conduct, and reporting of DURs.
本研究的目的是开发一种工具,以协助评估药物利用评价(DUR)和处方适宜性研究的方法学质量。
一个专家委员会遵循开发和测试新工具的公认步骤。向外部专家征求关于内容、表面效度和项目评分的意见。七名评分者测试了初始版本;随后,设计了一个改进的工具。埃德蒙顿药物利用评价质量评估工具(EQUATDUR-2)评估三个领域:样本选择(1项)、数据收集(1项)和数据分析(3项)。十六名评分者对DUR的随机样本测试了EQUATDUR-2。
研究测量指标为信度——使用个体评分者评分的随机效应组内相关系数(ICC2,1)和评分均值(ICC2,k)——以及DUR质量水平和评分者组之间的变异性。
在方法学质量(P<0.001)以及比较低质量、中等质量和高质量DUR的平均得分方面存在显著差异。非方法学家的评分表现出显著变异性(P = 0.03)且往往更高。各个项目的一致性有所不同(ICC2,1,0.22至0.44;ICC2,k,0.81至0.91),平均总结评分的一致性也有所不同(ICC2,1,0.42 [95% CI,0.28至0.61];ICC2,k,0.92 [95% CI,0.86至0.96])。对每个DUR进行评分的平均时间为10.0分钟(95% CI,9.2至10.9)。
EQUATDUR-2是一种简洁的、可自行使用的工具,具有效度和信度的证据。我们建议≥2名评分者独立评估每个DUR,并通过共识解决分歧。EQUATDUR-2将帮助临床医生和决策者评估DUR研究的质量,并为提高DUR设计、实施和报告的严谨性提供一个框架。